Perspective Therapeutics
Develops image-guided lead-212 cancer therapies with paired lead-203 imaging.
Something off on this page? Send us feedback.
Profile
Develops investigational, image-guided radiopharmaceutical therapies for cancers including neuroendocrine tumors, melanoma and solid tumors. Pairs lead-203 imaging with lead-212 treatment candidates and relies on clinical development, isotope supply and time-sensitive regional dose production instead of commercial product sales.
Develops image-guided, peptide-targeted alpha radiopharmaceuticals for cancer. Its theranostic approach uses lead-203 imaging to assess target expression and biodistribution, then pairs the same targeting construct with lead-212 to deliver alpha radiation to cancer cells. Lead programs address SSTR2-positive neuroendocrine tumors, MC1R-positive melanoma and FAP-alpha-positive solid tumors; all remain investigational.
Operates as a clinical-stage developer with grant-funded research and financing or strategic-partner economics rather than product sales. Research and clinical-dose production are centered in Iowa and New Jersey, alongside a planned U.S. manufacturing network. Development depends on patient selection and enrollment, regulatory progress, licensed intellectual property, isotope supply and time-sensitive production and delivery because lead-212 has a 10.6-hour half-life.
Company facts
Key statistics
Year to date +10.9% · Average volume (30d) 1.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Aug 18, 2026 | BMO Capital | Initiate | Outperform | $11 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | −$0.25 | −$0.22 | +12.4% | $90.5K | $81.0K | −10.5% | +6.00% |
| May 11, 2026Q1 FY26 | −$0.29 | −$0.25 | +13.8% | $157.4K | $76.0K | −51.7% | −2.84% |
| Mar 16, 2026Q4 FY25 | −$0.37 | −$0.51 | −37.8% | $232.5K | $43.0K | −81.5% | −5.17% |
| Nov 10, 2025Q3 FY25 | −$0.33 | −$0.35 | −6.1% | $244.4K | $209.0K | −14.5% | 0.00% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $342.0K | $290.0K | $209.0K | $43.0K | $76.0K | $81.0K | |
| Gross profit | −$390.0K | −$443.0K | −$566.0K | −$968.0K | −$1.1M | $81.0K | |
| Operating income | −$21.8M | −$24.0M | −$27.9M | −$39.8M | −$28.3M | −$29.3M | |
| Net income | −$18.2M | −$21.5M | −$26.0M | −$37.5M | −$26.2M | −$26.8M | |
| Diluted EPS | −$0.25 | −$0.30 | −$0.35 | −$0.51 | −$0.35 | −$0.36 | |
| Gross margin | -114.0% | -152.8% | -270.8% | -2,251.2% | -1,381.6% | 100.0% | |
| Operating margin | -6,383.6% | -8,289.3% | -13,330.6% | -92,632.6% | -37,211.8% | -36,121.0% |
Fiscal years (4-quarter sums)FY24 $1.5M · FY25 $884.0K
Balance sheet, Jun 30, 2026Cash & short-term investments $236.9M · Total debt $4.0M · Total assets $392.0M · Shareholders' equity $323.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 114.05M · Float 68.30M · 59.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Commodore Capital LP | 11.94M | 9.90% | 13G | Feb 9, 2026 |
| BlackRock, Inc. | 7.78M | 6.80% | 13G | Jul 29, 2026 |
| Qatar Investment Authority | 7.07M | 6.20% | 13G | Feb 5, 2026 |
| State Street Corporation | 6.05M | 5.30% | 13G | Aug 7, 2026 |
| Avidity Partners Management LP | 6.05M | 5.30% | 13G | Mar 10, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Novartis (ADR)
Approved SSTR2 NET radioligand therapy and deep platform scale.
- Bristol-Myers Squibb
Phase 3 SSTR2 alpha therapy for GEP-NETs.
- Lantheus
SSTR2 NET therapy and diagnostic pair with commercial rights.
- Telix Pharmaceuticals
FAP theranostics and Pb-212 manufacturing capabilities.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Perspective Therapeutics | $3.21 | +3.67% | $354.7M | — | — | 969.1 | −72.1% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Lantheus | $100.51 | −0.24% | $6.56B | 24.3 | 18.3 | 4.2 | +2.7% |
| Telix Pharmaceuticals | $11.29 | +0.18% | $3.82B | 113.3 | — | 4.0 | +22.8% |
| Median | 23.8 | 16.4 | 4.1 | +4.2% |